You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202171 - 202180 of 207726 results
  1. Vaccine discovery for Burkholderia via protection screen

    SBC: MACROGENICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Glanders is a severe disease that has already been used as a bioweapon. It is naturally an equine disease but can be administered by aerosol for efficient human infection. Even if quickly diagnosed as Burkholderia mallei and treated, antibiotics do not control infections well. No vaccine has been developed, yet is a rational component of any plan for defense. I ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  2. Vaccine-enhanced DLI to prevent cancer recurrence after stem cell transplantation

    SBC: CERUS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Delayed reconstitution of antigen-specific immunity following allogeneic hematopoietic stem cell transplantation (HSCT) predisposes patients to opportunistic infections and tumor recurrence. To address these problems, we are developing a vaccination methodology using a non-replicating but highly immunogenic Listeria monocytogenes (Lm) vector. When an Lm vaccine ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Vaccine-enhanced DLI to prevent cancer recurrence after stem cell transplantation

    SBC: CERUS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Delayed reconstitution of antigen-specific immunity following allogeneic hematopoietic stem cell transplantation (HSCT) predisposes patients to opportunistic infections and tumor recurrence. To address these problems, we are developing a vaccination methodology using a non-replicating but highly immunogenic Listeria monocytogenes (Lm) vector. When an Lm vaccine ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Vaccine enhancement through antigen targeting

    SBC: Iterative Therapeutics Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): There is currently a great need for new and more effective vaccines. Vaccines based on recombinant proteins, purified subunits, or peptides often elicit poor immune responses resulting in a failure to achieve vaccination. Our solution is to develop more effective vaccines that target antigens to antigen presenting cells more directly. In this Phase I proposal ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. Vaccine enhancement through antigen targeting

    SBC: Iterative Therapeutics Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): There is currently a great need for new and more effective vaccines. Vaccines based on recombinant proteins, purified subunits, or peptides often elicit poor immune responses resulting in a failure to achieve vacc

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. VACCINE FOR INFECTIOUS BURSAL DISEASE VIRUS

    SBC: Syntro Corp.            Topic: N/A

    THE IMMUNODOMINANT ANTIGEN OF INFECTIOUS BURSAL DISEASE VIRUS HAS BEEN SHOWN TO BE A 32 KD STRUCTURAL PROTEIN. MONOCLONAL ANTIBODY, DIRECTED AGAINST THE PROTEIN, PASSIVELY PROTECTS CHICKS. SYNTRO HAS CLONED THE ENTIRE LARGE GENOMIC RNA SEGMENT WHICH CODES FOR A SINGLE LARGE POLYPROTEIN THAT IS PROTEOLYTICALLY PROCESSED IN VIVO TO YIELD THE 32 KD ANTIGEN AND TWO OTHER PROTEINS. SYNTRO WILL CONSTRUC ...

    SBIR Phase II 1988 Department of Agriculture
  7. VACCINE FOR INFECTIOUS BURSAL DISEASE VIRUS

    SBC: Syntro Corp.            Topic: N/A

    N/A

    SBIR Phase I 1987 Department of Agriculture
  8. VACCINE FOR LEISHMANIASIS

    SBC: Corpixa Corp.            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  9. Vaccine for Mycobacterium Tuberculosis

    SBC: Corpixa Corp.            Topic: N/A

    The goal of this investigation is to develop the invasin gene as a vaccine against M. tuberculosishuman host. Up to the present time, the only known and generally accepted vaccine-BCG-is a living athas shown variable efficacy in the countries where it has been used. Although efforts by other invesof obtaining non-viable vaccine have not proved successful, the concept of a new candidate vaccine cpr ...

    SBIR Phase I 1995 Department of Health and Human Services
  10. VACCINE/HEALTH ECONOMICS LINEAR PROGRAMMING SOFTWARE

    SBC: MEDICAL DECISION ASSOCIATES, INC.            Topic: N/A

    N/A

    SBIR Phase I 1998 Department of Health and Human Services
US Flag An Official Website of the United States Government